Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.950
-0.680-3.65%
Volume:4.10M
Turnover:74.00M
Market Cap:47.73B
PE:15.20
High:18.550
Open:18.550
Low:17.710
Close:18.630
52wk High:29.000
52wk Low:12.535
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:2.30
T/O Rate:0.76%
Dividend:0.35
Dividend Rate:1.95%
EPS(LYR):1.181
ROE:6.75%
ROA:1.32%
PB:0.87
PE(LYR):15.20
PS:1.06

Loading ...

Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection

Bulletin Express
·
Mar 20

FOSUN PHARMA Subsidiary Gains Approval for Phase I Trial of HLX18 in Solid Tumors

Stock News
·
Mar 20

FOSUN PHARMA's Sodium Thiosulfate Injection Receives Regulatory Approval

Stock News
·
Mar 20

Fosun Pharma (02196): Subsidiary MicroH Therapeutics Secures NMPA Green Light for Phase I Trial of LBP-ShC4 Live Biotherapeutic

Bulletin Express
·
Mar 16

FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

Stock News
·
Mar 16

Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug

MT Newswires Live
·
Mar 16

FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683

Bulletin Express
·
Mar 13

FOSUN PHARMA Subsidiary Gains Approval for Clinical Trial of FXS0683 Tablets

Stock News
·
Mar 13

FOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316

Stock News
·
Mar 09

Fosun Pharma (02196) Sets 24 March 2026 Board Meeting to Review FY 2025 Results and Final Dividend Proposal

Bulletin Express
·
Mar 09

Fosun Pharmaceutical Gets Nod for Phase I Trial of Tumor Drug Candidate; Hong Kong Shares Up 5%

MT Newswires Live
·
Mar 06

Hong Kong Market Analysis: Strait Restrictions Eased, Focus on NPC Press Conference

Stock News
·
Mar 05

FOSUN PHARMA Subsidiary Receives Approval for Phase I Clinical Trial of HLX97 in Advanced/Metastatic Solid Tumors

Stock News
·
Mar 05

FOSUN PHARMA (02196) Announces February 2026 Monthly Return with Unchanged Share Capital

Bulletin Express
·
Mar 05

From Following to Leading: FOSUN PHARMA's Global Innovation Journey

Deep News
·
Mar 02

Fosun Pharmaceutical (02196) Announces Poll Results of 2026 EGM and Class Meetings

Bulletin Express
·
Feb 27

Fosun Pharma Gets Regulatory Nod for 6 Billion Yuan Bond Issue

MT Newswires Live
·
Feb 26

FOSUN PHARMA Secures Regulatory Approval for Bond Offering to Professional Investors

Stock News
·
Feb 26

Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China

MT Newswires Live
·
Feb 25

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK, 600196.SH) Receives NMPA Approval for Phase II Clinical Trial of Luvometinib in KRAS-Mutant NSCLC

Bulletin Express
·
Feb 25